Company: Precigen
Title: President and CEO
Industry: Healthcare
Standout achievement in 2025: Led Precigen through its first FDA approval and commercial launch with PAPZIMEOS, the first and only approved therapy for recurrent respiratory papillomatosis (RRP).
With the FDA approval and commercial launch of PAPZIMEOS, the rare-disease treatment breakthrough moved Precigen from the research and clinical stage to a fully commercial stage biopharmaceutical company focused on precision medicine for underserved rare disease populations.
Sabzevari, who previously co-founded Boston-based Compass Therapeutics and held executive roles at Merck KGaA/EMD Serono and the National Cancer Institute, is overseeing a pipeline of Precigen therapies across immuno-oncology, autoimmune disorders, and infectious diseases.
